{"entity":{"id":"m701","kind":"drug","name":"M701","aka":[],"tldr":"M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.","summary":"Malignant ascites, fluid that builds up in the abdomen from cancer spread to the peritoneum, is drained repeatedly for symptom relief. Catumaxomab, an EpCAM-CD3 bispecific, was approved in Europe in 2009 for this use and later withdrawn. M701 revives the approach: YZY Biopharma's phase 3 trial in China compares intraperitoneal M701 with paracentesis alone for the time until fluid must be drained again.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of M701","url":"https://clinicaltrials.gov/search?intr=M701"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","gastric"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["epcam","cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06432296"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"modality":"Bispecific antibody (EpCAM x CD3), intraperitoneal","mechanism":"One arm binds EpCAM on tumour cells in the ascites fluid and the other engages CD3 on T cells, bringing T cells to kill the cancer cells that cause malignant ascites, the mechanism of the earlier drug catumaxomab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/m701/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"}],"trial":[{"id":"nct06432296","kind":"trial","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","route":"/trials/nct06432296/"}]}}